Literature DB >> 11891148

Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.

Matthias Griese1, I Müller, D Reinhardt.   

Abstract

The optimal treatment for the eradication of initial P. aeruginosa infection in CF is still unclear. Recently long-term inhaled tobramycin has been proposed. Here we report the results with brief inhaled and/or systemic anti-pseudomonal treatments. Initial P. aeruginosa colonization was successfully eradicated as demonstrated by negative repetitive throat cultures or sputa and serum antipseudomonal antibodies in 15 of 17 patients for at least two years. Randomized, controlled trials are urgently needed to define the optimal protocol for the eradication of P. aeruginosa. Pseudomonas aeruginosa, infection, treatment, antibodies; inhaled tobramycin

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891148

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  11 in total

Review 1.  Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the New.

Authors:  George A O'Toole
Journal:  J Bacteriol       Date:  2018-01-24       Impact factor: 3.490

Review 2.  Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Authors:  Samuel M Moskowitz; Ronald L Gibson; Eric L Effmann
Journal:  Pediatr Radiol       Date:  2005-05-03

Review 3.  Inhaled anti-infective agents: emphasis on colistin.

Authors:  A Michalopoulos; E Papadakis
Journal:  Infection       Date:  2010-02-27       Impact factor: 3.553

Review 4.  Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature.

Authors:  Federico Marchetti; Luisella Giglio; Manila Candusso; Dino Faraguna; Baroukh M Assael
Journal:  Eur J Clin Pharmacol       Date:  2004-03-05       Impact factor: 2.953

5.  Multiple-locus variable-number tandem-repeat analysis for longitudinal survey of sources of Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  Hoang Vu-Thien; Gaëlle Corbineau; Katia Hormigos; Brigitte Fauroux; Harriet Corvol; Annick Clément; Gilles Vergnaud; Christine Pourcel
Journal:  J Clin Microbiol       Date:  2007-08-15       Impact factor: 5.948

Review 6.  Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Simon C Langton Hewer; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-04-25

Review 7.  Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis.

Authors:  Rashmi Ranjan Das; Sushil Kumar Kabra; Meenu Singh
Journal:  ScientificWorldJournal       Date:  2013-12-30

8.  Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections.

Authors:  Alya Heirali; Suzanne McKeon; Swathi Purighalla; Douglas G Storey; Laura Rossi; Geoffrey Costilhes; Steven J Drews; Harvey R Rabin; Michael G Surette; Michael D Parkins
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

9.  Phenotypic characterization and PCR-Ribotypic profile of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Iran.

Authors:  Hossein Fazeli; Reza Akbari; Sharare Moghim; Bahram Nasr Esfahani
Journal:  Adv Biomed Res       Date:  2013-03-06

10.  Structural basis for substrate specificity in ArnB. A key enzyme in the polymyxin resistance pathway of Gram-negative bacteria.

Authors:  Myeongseon Lee; Marcelo C Sousa
Journal:  Biochemistry       Date:  2014-01-24       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.